Main Article Content

Vikas Kumar Pandey
Manveen Kaur
Anita Patel


Aminoglycoside, Treatment, kidney injury, Drugs, Patients, GFR


The semi-synthetic or natural antibiotics known as aminoglycosides are produced by actinomycetes. They were some of the first antibiotics to be created for clinical use, and some of them have been approved for use in patients. Strong antibiotics like aminoglycosides work to stop the synthesis of new proteins, which is the main goal of all antibiotics. Aminoglycosides are used in the treatment of a wide range of illnesses, including bone infections, external burns, cystic fibrosis, diarrhoea, endocarditis, febrile neutropenia, fish tapeworm infections, hepatic encephalopathy, intra-abdominal infections, joint infections, kidney infections, meningitis, pelvic inflammatory disease, peritonitis, skin or soft tissue infections, and urinary tract infections. However, reduced renal function and hearing loss are the most frequent side effects of aminoglycosides. Aminoglycosides must be supplied intravenously because oral administration results in inadequate absorption. When other antibiotics are either ineffective or inappropriate, aminoglycosides are frequently utilised.  The following aminoglycoside resistance mechanisms exist: (a) deactivating aminoglycosides through N-acetylation, adenylylation, or O-phosphorylation; (b) lowering the intracellular concentration of aminoglycosides through changes to the flexibility of the outer membrane; (c) inhibiting active efflux; and (d) drug trapping; and (e) mutating the 30S ribosomal subunit target. These are all examples of resistance mechanisms. As antibiotic resistance grows around the world, aminoglycosides are becoming more crucial in medical therapy. In this essay, I will examine which aminoglycoside antibiotic damages kidney cells most severely and examine the pharmacological therapy paradigm that is currently in use. Everything revolves around improving patient safety and results.

Abstract 170 | pdf Downloads 92


1. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An Overview. Cold Spring Harbor Perspectives in Medicine. 2016;6(6):a027029.
2. Germovsek E, Barker CI, Sharland M. What do I need to know about aminoglycoside antibiotics? Archives of disease in childhood Education and practice edition. 2017;102(2):89-93. doi:
3. Uis S. Gonzalez I, Spencer JP. Aminoglycosides: A Practical Review. American Family Physician. 1998;58(8):1811-1820. ntamicin%20is%20the%20most%20commonly
4. List of Aminoglycosides.
5. UpToDate. Accessed July 10, 2023.
nephrotoxicity#:~:text=Aminoglycosides%20are%20freely%20filtered%20a cross
6. Laurent G, Kishore BK, Tulkens PM. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochemical Pharmacology. 1990;40(11):2383-2392.
7. Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria – a description of the action, resistance mechanism, and nosocomial battleground. Journal of Biomedical Science. 2007;15(1):5-14. doi:
8. Block M, Blanchard DL. Aminoglycosides. PubMed. Published 2023.
9. Chaves BJ, Tadi P. Gentamicin. PubMed. Published 2022.
10. tobramycin injection, USP Clinical Pharmacology | Pfizer Medical Information - US. Accessed July 28, 2023.
11. Sizar O, Rahman S, Sundareshan V. Amikacin. PubMed. Published 2022.
12. Veirup N, Kyriakopoulos C. Neomycin. PubMed. Published 2023. Accessed July 28, 2023. ns-
13. Plazomicin.
14. Waters M, Tadi P. Streptomycin. PubMed. Published 2022.
15. Garneau-Tsodikova S, Labby KJ. Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. MedChemComm. 2016;7(1):11-27.
16. Doi Y, Wachino J, Arakawa Y. Aminoglycoside Resistance. Infectious Disease Clinics of North America. 2016;30(2):523-537. doi:
17. UpToDate. Accessed July 30, 2023.
18. Halouzková BA, Hartinger JM, Krátký V, Tesař V, Slanař O. Dosing of Aminoglycosides in Chronic Kidney Disease and End-Stage Renal Disease Patients Treated with Intermittent Hemodialysis. Kidney and Blood Pressure Research. Published online April 20, 2022:1-11. doi:
19. Chou CL, Chuang NC, Chiu HW, Liao CT, Hsu YH, Chang TH. Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease. Scientific Reports. 2022;12(1):17212. doi:
20. Paquette F, Bernier-Jean A, Brunette V, et al. Acute Kidney Injury and Renal Recovery with the Use of Aminoglycosides: A Large Retrospective Study. Nephron. 2015;131(3):153-160. doi:
21. Nenad Stojiljkovic, Stoiljkovic M, Mihailovic D, et al. Beneficial Effects of Calcium Oral Coadministration in Gentamicin-Induced Nephrotoxicity in Rats. 2012;34(5):622-627. doi:
22. Pickkers P, Darmon M, Hoste E, et al. Acute kidney injury in the critically ill: an updated review on pathophysiology and management. Intensive Care Medicine. 2021;47(8):835-850. doi:
23. Mattie H. Efficacy and nephrotoxicity of aminoglycosides. Published online January 1, 1991:55-63. doi:
24. Published 2023.
25. Appel GB. Aminoglycoside nephrotoxicity. The American Journal of Medicine. 1990;88(3):S16-S20. doi:
26. Kotler Donald P, Sordillo Emilia M. Nutritional Status and Aminoglycoside Dosing. Clinical Infectious Diseases. 1998;26(1):249250. doi: